PORT-77

DRUG3 trials

Sponsors

Portal Therapeutics, Inc.

Conditions

EPP2Erythropoietic Protoporphyria (EPP)Healthy Adult ParticipantsX-Linked Protoporphyria (XLP)

Phase 1

Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of PORT-77 Administered to Healthy Adult Participants

CompletedNCT06346509

Portal Therapeutics, Inc.Healthy Adult Participants

Start: 2024-04-08End: 2026-01-20Updated: 2026-04-20

Phase 2

GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria

CompletedNCT06971900

Portal Therapeutics, Inc.Erythropoietic Protoporphyria (EPP)

Start: 2025-04-04End: 2025-11-24Updated: 2026-07-29

A Study to Investigate PORT-77 Oral Dosing Compared With Placebo in Participants With Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP)

RecruitingNCT07820085

Portal Therapeutics, Inc.EPP2, Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)

Start: 2026-09-01End: 2029-09-01Target: 225Updated: 2026-09-15

Related Papers

PORT-77 is a potent inhibitor of ABCG2 that reduces efflux of protoporphyrin IX from erythrocytes of patients with protoporphyria and reduces plasma protoporphyrin IX levels in healthy human subjects

Blood2025-11-03